
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc has demonstrated a robust trajectory in revenue growth, with Q3 FY25 revenue reaching $18,942, reflecting a 31% year-over-year increase driven primarily by an 89% surge in Nociscan report volumes, indicative of strong market demand for its proprietary technology. The company is actively expanding its presence through strategic commercial agreements with prominent healthcare institutions, which could further enhance its market penetration and revenue stability. Notably, the increased spending on sales and marketing, particularly tied to the CLARITY trial and improvements in UK payor coverage, suggests a commitment to long-term growth and profitability potential in the healthcare technology sector.
Bears say
Aclarion Inc faces significant financial challenges, including slower-than-expected traction with both surgeons and payers, which hampers revenue growth potential for its Nociscan product. The company is also experiencing rising marketing and administrative expenses, leading to a downward revision of its FY25 earnings per share estimates, which are now projected to be substantially negative. Moreover, underlying risks such as balance sheet concerns, regulatory hurdles, and competitive pressures further contribute to a negative outlook for Aclarion's stock performance.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares